Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Defence Therapeutics Announces Convertible Debenture Conversion

By The Northwire Desk — AI Analysis Nov 21, 2025 · 18:03 DTC · 0.78 Defence Therapeutics Inc.
DTC · Price

Executive Summary

  • Defence Therapeutics announced the full conversion of its 8% convertible debentures (issued Nov 16, 2024) into 2,607,600 common shares on the maturity date of Nov 16, 2025.
  • The conversion represents a principal amount of $1,476,000 converted at $0.60 per share (2,460,000 shares) plus accrued interest of $118,080 converted at $0.80 per share (147,600 shares).
  • The transaction eliminates the outstanding debenture liability and increases common equity by approximately $1.59 million.

Key Details

  • Debentures Converted: 8% convertible debentures issued Nov 16, 2024.
  • Principal Amount Converted: $1,476,000 → 2,460,000 shares at $0.60 per share.
  • Accrued Interest Converted: $118,080 → 147,600 shares at $0.80 per share.
  • Total Shares Issued on Conversion: 2,607,600 common shares.
  • Aggregate Value of Conversion: $1,594,080 (principal + interest).
  • Effect on Capital Structure: Full extinguishment of the debenture liability; increase in outstanding common shares and equity base.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Defence Therapeutics Inc.

May 19, 2026 · 03:16

Defence Therapeutics Bolsters ADC Platform Execution Amidst Capital Market Skepticism

Production / Operations Mar 09, 2026 · 14:53

Defence Therapeutics closes $9.59M private placement

Financings Feb 27, 2026 · 20:41

Defence Therapeutics arranges $11-million financing

Financings Feb 27, 2026 · 17:01

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Financings Jan 28, 2026 · 18:24

Defence, Cdn Nuclear Laboratories expand work program

M&A / Property Jan 28, 2026 · 08:40

Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

Other